Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And this bodes well for OMS906 and it's expanding range of potential indications |
| In the interest of time I'll focus on only two, our adoptive cell therapy and our cancer vaccine platforms specifically what we believe will prove out to be their respective major advantages over our competitor programs |
| As with our other molecular IO platforms immunomodulators and immunotoxins, we're excited about the potential of our cancer vaccine platform as well and the potential for that platform to have a significant impact on the survival of cancer patients |
| And three, OMS906 should deliver better patient convenience and compliance than the competition, by allowing once-quarterly intravenous and subcutaneous administration |
| As a result, OMS906 should maintain more consistent pathway inhibition than drugs targeting factor B, C3 or C5 providing better protection against potentially life-threatening breakthrough of a patient's underlying disease |
| Together with enhanced efficacy by enabling multiple repetitive administrations, the expected result is better and sustained anti-tumor response |
| To anyone paying attention to our programs and their development progress, it should be clear that our company is strong and well-positioned for success |
| They help us by continuing to validate indications clinically, providing a de-risked roadmap for us to follow, with what we expect is a better target, MASP-3, and a better drug OMS906 |
| We've also made good progress in our orally-administered MASP-2 inhibitor program |
| As compassionate-use results show more and more evidence of strong survival outcomes we feel an increasingly strong obligation to provide access narsoplimab for high-risk TA-TMA patients while the drug continues to proceed through the regulatory process |
| So I think the results are even more impressive, given what we would expect to be the severity of the patients and the fact that a good number of them have failed prior treatment with other off-label drugs and then we see this response with narsoplimab |
| So the data around OMS-906 continue to strengthen and the breadth of potential indications continues to expand |
| As a result, the value story for the entirety of the 906 program continues to improve |
| This would be a win-win for patients, physicians, and the payer system |
| I hope that today's presentation helped to identify the opportunities for value creation across our late-stage and even our earlier-stage programs |
| So despite the outcome of ARTEMIS-IGAN, the evidence supporting the role of the lectin pathway and kidney disease and the therapeutic potential of MASP-2 inhibition remained strong |
| If needed, this immune memory could be further enhanced with subsequent vaccine boosters |
| As I stated earlier, this analysis plan has been put together not by Omeros, but by an external and very well-respected, well-known bio statistical group |
| While we expect these three major advantages to provide significant differentiation over our competitors, those competitors also help us |
| Our work with narsoplimab in COVID-19 and acute respiratory distress syndrome or ARDS, presents another opportunity for continued development of narsoplimab in a group of indications centered around ARDS for which there is strong and widely-published mechanistic evidence as well as proof-of-concept clinical data |
| Everyone at Omeros is working hard to recover, sustain and ultimately grow value for our shareholders following the ARTEMIS-IGAN results |
| This would represent a major advance over currently available T-cell therapies markedly decreasing both cost and preparation time |
| We believe that the moderate investment required to continue advancing our I-O program could create opportunities for meaningful non-dilutive funding |
| Clearly we're receiving positive feedback from them |
| Narsoplimab is particularly well suited for diseases like ARDS, acute indications requiring hospitalization |
| We also believe that our assays utility could well expand beyond acute COVID to include both long COVID and other disease related ARDS |
| While we expect to resolve these and other questions that we have on the ARTEMIS-IGAN trial, our top priorities are focused on near-term value-driving catalysts, specifically one, achieving approval and successful market launch for our narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy or TA-TMA mid next year |
| As in all other studies narsoplimab was generally well tolerated without any safety signals of concern |
| This should lead to more effective antitumor responses |
| Treatment of infected mice with a MASP-2 inhibitor significantly reduced disease severity scores and improved survival rates compared to the control antibody, specifically MASP-2 inhibition significantly reduced lung infiltrates adenoma and hemorrhage while also significantly reducing and normalizing brain inflammation and associated hyper activation of brain microglia |
| Statement |
|---|
| On October 16, we announced genuinely, surprising and disappointing preliminary results of the prespecified interim analysis in our Phase three ARTEMIS-IGAN trial, evaluating narsoplimab for the treatment of IgA nephropathy |
| For the third quarter, our royalties on OMIDRIA net sales were $10 million, down $700,000 from the second quarter |
| Depression of the reward system results in diminished enjoyment of other life activities, food, socialization, sex, sports |
| To date, the challenges in assessing a therapeutic in long COVID are the lack of standardization in diagnostic criteria and in clinical endpoints |
| Though, widely pursued successful development of therapeutic cancer vaccines remains difficult to achieve |
| OMIDRIA royalties for the third quarter were $10 million and that's a $700,000 decrease over second quarter royalties |
| This is consistent with the historical decline in cataract procedures during the summer months |
| Our net loss for the third quarter was $37.8 million or $0.60 per share compared to a net loss of $37.3 million or $0.59 per share in the second quarter of this year |
| Our net loss for the third quarter of 2023 was $37.8 million or $0.60 per share compared to a net loss of $37.3 million or $0.59 per share in the second quarter of this year |
| Please refer to the special note regarding forward-looking statements in the company's quarterly report on Form 10-Q which was filed today with the SEC and the Risk Factors section of the company's most recent annual report on Form 10-K for a discussion of these risks and uncertainties |
| All forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially |
| So we don't see any of those other components resulting in a delay |
| Interest expense for Q4 will be approximately $7 million, down $900,000 from the third quarter due to the November 15th retirement of the 2023 notes |
| Based on the absence of a statistically significant improvement on the proteinuria endpoint and as agreed with FDA, the clinical trial has been discontinued |
| These are for the most part obviously very sick patients |
| But at some point it really does become I think, untenable |
| Under the terms of the contract, the applicable royalty rate decreased from 50% to 30% of US net sales, upon earning the $200 million milestone payment at the end of last year |
Please consider a small donation if you think this website provides you with relevant information